zidesamtinib
zidesamtinib is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand name including JIDEYTRO. Available dosage form: tablet, film coated.
Drug details
- Generic Name
- zidesamtinib
- Brand Names
- JIDEYTRO
- Application Number
- NDA220185
- Sponsor
- Patheon Inc.
- NDC Codes
- 4
- Dosage Forms
- TABLET, FILM COATED
- Routes
- ORAL
- Active Ingredients
- ZIDESAMTINIB
Indications and Usage
1 INDICATIONS AND USAGE JIDEYTRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor [see Dosage and Administration ( 2.1 ), Clinical Studies ( 14.1 )] . JIDEYTRO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor.( 1 )